Current Report Filing (8-k)
September 18 2020 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 14, 2020
BIOANALYTICAL SYSTEMS, INC.
|
(Exact name of registrant as specified in its charter)
|
Indiana
|
|
0-23357
|
|
35-1345024
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
|
|
47906-1382
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act
|
|
Name of each exchange
|
Title of each class
|
Trading Symbol(s)
|
on which registered
|
Common Shares
|
BASi
|
NASDAQ Capital Market
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note: This Current Report
on Form 8-K is being furnished to provide the information contained in Items 2.02 and 9.01 below which was previously inadvertently
not furnished due to an administrative error.
The information provided in Item 2.02 and
Item 9.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 and Item
9.01 of this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended.
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 14, 2020,
Bioanalytical Systems, Inc. issued a press release announcing results for the three and nine months of fiscal 2020 ended June 30,
2020. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Bioanalytical Systems, Inc.
|
|
|
|
|
|
|
|
|
Date: September 18, 2020
|
By:
|
Beth A. Taylor
|
|
|
|
Chief Financial Officer,
|
|
|
|
Vice President—Finance
|
|
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Sep 2023 to Sep 2024